---
title: "Vigil Neuroscience Inc Provided An Update On Company's Small Molecule Trem2 Agonist, Vg-3927"
description: "Oct 12 (Reuters) - Vigil Neuroscience Inc:"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/99780403.md"
published_at: "2023-10-12T20:21:15.000Z"
---

# Vigil Neuroscience Inc Provided An Update On Company's Small Molecule Trem2 Agonist, Vg-3927

> Oct 12 (Reuters) - Vigil Neuroscience Inc:

Oct 12 (Reuters) - Vigil Neuroscience Inc (VIGL.O) :

-   VIGIL NEUROSCIENCE INC - PROVIDED AN UPDATE ON COMPANY’S SMALL MOLECULE TREM2 AGONIST, VG-3927
    
-   VIGIL NEUROSCIENCE - GOT 30-DAY RESPONSE LETTER FROM U.S. FDA REGARDING PREVIOUSLY COMMUNICATED PARTIAL CLINICAL HOLD ON IND APPLICATION FOR VG-3927
    
-   VIGIL NEUROSCIENCE - LETTER SAYS EXTRA NON-CLINICAL DATA NEEDS TO BE PROVIDED TO EXCEED MAXIMUM EXPOSURE LIMIT IN PHASE 1 TRIAL EVALUATING VG-3927
    
-   VIGIL NEUROSCIENCE INC - IN PROCESS OF OBTAINING ADDITIONAL PHARMACOKINETIC DATA AND WILL WORK WITH FDA TO ADDRESS PARTIAL CLINICAL HOLD Further company coverage: (VIGL.O)

### Related Stocks

- [VIGL.US - Vigil Neuroscience](https://longbridge.com/en/quote/VIGL.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Key facts: Sanofi acquires Vigil Neuroscience for $470 million; Formycon shares rise 8% | Sanofi acquired Vigil Neuroscience for $470 million, with a potential $600 million contingent payment, to develop a firs | [Link](https://longbridge.com/en/news/266288325.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.